Plenary Paper MYELOID NEOPLASIA Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany; German Consortium for Translational Cancer Research, Heidelberg, Germany; Department of Internal Medicine III, Ulm University, Ulm, Germany; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Haematology, Cambridge Institute of Medical Research, and Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; Department of Hematology and Oncology, Eberhard Karls University, Tübingen, Germany; Department of Hematology and Oncology, Otto von Guericke University, Magdeburg, Germany; Clinical Cooperation Unit Molecular Hematology and Oncology, German Cancer Research Center, and Department of Internal Medicine V, Ruprecht Karls University, Heidelberg, Germany; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA; Leukemia Center, Human Oncology and Pathogenesis Program and Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY; Immune Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, PA; and Heidelberg Institute for Stem Cell Technology and Experimental Medicine and Division of Stem Cells and Cancer, Experimental Hematology Group, German Cancer Research Center, Heidelberg, Germany